From: Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
Study | Study population | Methods | Results | |||||||
---|---|---|---|---|---|---|---|---|---|---|
 | N | Location | TB | Median CD4+ cells/mm3(IQR) | Timing of ART in weeks ‘earlier’ vs ‘later’ | Primary endpoint | Follow-up in months | Primary endpoint ‘earlier’ vs ‘later’a | Primary endpoint in CD4 <50 cells/μlb | TB immune reconstitution |
SAPIT [48] (first analysis) | 429 | South Africa | Smear-positive pulmonary TB | 150 (77 to 254) | <12 vs after end TB treatment | Death | 12.1 | 5.4 vs 12.1 P = 0.003c | Not reported | 12.4% vs 3.8% P <0.001 |
SAPIT [96] (second analysis) | 429 | South Africa | Smear-positive pulmonary TB | 150 (77 to 254) | Within 4 vs 8 to 12 | AIDS or death | 17.7 | 6.9 vs 7.8 P = 0.73 | 8.5 vs 26.3b P = 0.06 | 20.1% vs 7.7% P <0.001 |
CAMELIA [95] | 660 | Cambodia | Smear-positive TB | 25 (11 to 56) | 2 vs 8 | Death | 25 | 18% vs 27%, P = 0.006 | Not reportedd | 33.1% vs 13.7% P <0.001 |
STRIDE [55] | 809 | Multicontinente | Confirmed or presumed pulmonary or extrapulmonary TB | 77 (36 to 145) | 2 vs 8 to 12 | AIDS or death | 12 | 12.9% vs 16.1% P = 0.45 | 15.5% vs 26.6% P = 0.02 | 11% vs 5% P = 0.02 |
TB Meningitis [97] | 253 | Vietnam | TB meningitis | 39 (18 to 116) | ≤1 vs 8 | Deathf | 12 | 59.8% vs 55.6% P = 0.50 | 63.3% vs 65.1% P = 0.84 | Not reported |
TIME Trial [98] | 156 | Thailand | Confirmed or presumed pulmonary or extrapulmonary TB | 43 (37 to 106) | 4 vs 12 | Death | 96 weeks | 7.6% vs 6.5% P >0.99 | 8.7% vs 13.1% P = 0.725 | 8.86 vs 5.02 P = 0.069 |